Our R&D

Notes: The trademarks and registered trademarks within are the property of their respective owners. *Greater China trial in preparation or under planning. **Greater China trial to initiate in 2025 or under planning. Greater China = mainland China, Hong Kong, Macau and Taiwan, collectively. (1) Combination with carboplatin and KEYTRUDA +/- bevacizumab; (2) Zai Lab has exclusive license to develop and commercialize of povetacicept in mainland China, Hong Kong, Macau, Taiwan, and Singapore; (3) Zai Lab has exclusive license to develop and commercialize SUL-DUR in mainland China, Hong Kong, Taiwan, Macau, Korea, Vietnam, Thailand, Cambodia, Laos, Malaysia, Indonesia, the Philippines, Singapore, Australia, New Zealand, and Japan.

Ongoing Clinical Trials

For more information about the above trials, please visit https://clinicaltrials.gov